Yoram Barak1, Dana Fridman2. 1. The University of Otago Medical School, Dunedin, New Zealand Yoram.Barak@otago.ac.nz. 2. School of Design, Victoria University of Wellington, Wellington, New Zealand.
Abstract
BACKGROUND: Cancer is a major public health problem worldwide, and the number of incident cases increases every year expected to reach 17.1 million a year by 2020. There is evidence that people who adhere to the Mediterranean Diet (MediD) have lower incidence of cancer. However, cancers' location and culture studies seem to affect the MediD impact. We aimed to review these discrepant findings. MATERIALS AND METHODS: A critical review from a focused literature search was conducted. A literature search of controlled trials from: EMBASE (1970-), MEDLINE (1950-) and PsycINFO (1960-) was undertaken. Two authors (DF and YB) independently extracted the data. RESULTS: Out of 785 abstracts identified only 583 publications focused solely on MediD and cancer. Of these, 46 were clinical trials published since 2007. Twenty-eight trials with a total of 570,262 participants are included in accordance with inclusion criteria. Only four reported the MediD does not reduce the risk of cancer. Of the negative studies, three were undertaken in non-Mediterranean populations. Cancers of the digestive tract were studied in 11 studies. Except for pancreatic cancer, all other sites along the digestive tract demonstrated significantly reduced rate with the MediD. CONCLUSION: The MediD is associated with reduction in overall cancer rates as well as significantly lower rates of digestive tract cancers. These effects may be accentuated in the Mediterranean countries themselves. Further studies are needed to support or refute the effects of the MediD on other cancer types. Copyright
BACKGROUND:Cancer is a major public health problem worldwide, and the number of incident cases increases every year expected to reach 17.1 million a year by 2020. There is evidence that people who adhere to the Mediterranean Diet (MediD) have lower incidence of cancer. However, cancers' location and culture studies seem to affect the MediD impact. We aimed to review these discrepant findings. MATERIALS AND METHODS: A critical review from a focused literature search was conducted. A literature search of controlled trials from: EMBASE (1970-), MEDLINE (1950-) and PsycINFO (1960-) was undertaken. Two authors (DF and YB) independently extracted the data. RESULTS: Out of 785 abstracts identified only 583 publications focused solely on MediD and cancer. Of these, 46 were clinical trials published since 2007. Twenty-eight trials with a total of 570,262 participants are included in accordance with inclusion criteria. Only four reported the MediD does not reduce the risk of cancer. Of the negative studies, three were undertaken in non-Mediterranean populations. Cancers of the digestive tract were studied in 11 studies. Except for pancreatic cancer, all other sites along the digestive tract demonstrated significantly reduced rate with the MediD. CONCLUSION: The MediD is associated with reduction in overall cancer rates as well as significantly lower rates of digestive tract cancers. These effects may be accentuated in the Mediterranean countries themselves. Further studies are needed to support or refute the effects of the MediD on other cancer types. Copyright
Authors: Genevieve Buckland; Antonio Agudo; Leila Luján; Paula Jakszyn; H Bas Bueno-de-Mesquita; Domenico Palli; Heiner Boeing; Fátima Carneiro; Vittorio Krogh; Carlotta Sacerdote; Rosario Tumino; Salvatore Panico; Gabriella Nesi; Jonas Manjer; Sara Regnér; Ingegerd Johansson; Roger Stenling; María-José Sanchez; Miren Dorronsoro; Aurelio Barricarte; Carmen Navarro; J Ramón Quirós; Naomi E Allen; Timothy J Key; Sheila Bingham; Rudolf Kaaks; Kim Overvad; Majken Jensen; Anja Olsen; Anne Tjønneland; Petra H M Peeters; Mattijs E Numans; Marga C Ocké; Françoise Clavel-Chapelon; Sophie Morois; Marie-Christine Boutron-Ruault; Antonia Trichopoulou; Pagona Lagiou; Dimitrios Trichopoulos; Eiliv Lund; Elisabeth Couto; Paolo Boffeta; Mazda Jenab; Elio Riboli; Dora Romaguera; Traci Mouw; Carlos A González Journal: Am J Clin Nutr Date: 2009-12-09 Impact factor: 7.045
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: V Benetou; A Trichopoulou; P Orfanos; A Naska; P Lagiou; P Boffetta; D Trichopoulos Journal: Br J Cancer Date: 2008-07-08 Impact factor: 7.640
Authors: Thomas Kostaropoulos; Louis Papageorgiou; Spyridon Champeris Tsaniras; Dimitrios Vlachakis; Elias Eliopoulos Journal: In Vivo Date: 2018 Sep-Oct Impact factor: 2.155
Authors: Cristina-Mihaela Lăcătușu; Elena-Daniela Grigorescu; Mariana Floria; Alina Onofriescu; Bogdan-Mircea Mihai Journal: Int J Environ Res Public Health Date: 2019-03-15 Impact factor: 3.390
Authors: Samuel Manzano-Carrasco; Jose Luis Felipe; Javier Sanchez-Sanchez; Antonio Hernandez-Martin; Leonor Gallardo; Jorge Garcia-Unanue Journal: Nutrients Date: 2020-06-04 Impact factor: 5.717